Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Nov 9;8:543–554. doi: 10.2147/DMSO.S90662

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Seufert. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Pharmacologic options for the treatment of T2DM: SGLT2 inhibition in the kidneys complements existing treatment options through an insulin-independent mechanism of action.

Notes: Adapted from Seufert J. SGLT-2 inhibition with canagliflozin: a new option for the treatment of type 2 diabetes. Dtsch Med Wochenschr. 2014;139(Suppl 2): S52–S58. © Georg Thieme Verlag KG.²¹

Abbreviations: T2DM, type 2 diabetes mellitus; SGLT2, sodium glucose cotransporter 2; GLP-1, glucagon-like peptide-1; DPP-4, dipeptidyl peptidase-4.